These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 20227407)

  • 41. Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice.
    Zala D; Bensadoun JC; Pereira de Almeida L; Leavitt BR; Gutekunst CA; Aebischer P; Hayden MR; Déglon N
    Exp Neurol; 2004 Jan; 185(1):26-35. PubMed ID: 14697316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease.
    Ramaswamy S; McBride JL; Han I; Berry-Kravis EM; Zhou L; Herzog CD; Gasmi M; Bartus RT; Kordower JH
    Neurobiol Dis; 2009 Apr; 34(1):40-50. PubMed ID: 19150499
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease.
    Vamos E; Voros K; Vecsei L; Klivenyi P
    Biomed Pharmacother; 2010 Apr; 64(4):282-6. PubMed ID: 19932584
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cell type-specific localization of optineurin in the striatal neurons of mice: implications for neuronal vulnerability in Huntington's disease.
    Okita S; Morigaki R; Koizumi H; Kaji R; Nagahiro S; Goto S
    Neuroscience; 2012 Jan; 202():363-70. PubMed ID: 22155493
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment.
    Zala D; Benchoua A; Brouillet E; Perrin V; Gaillard MC; Zurn AD; Aebischer P; Déglon N
    Neurobiol Dis; 2005 Dec; 20(3):785-98. PubMed ID: 16006135
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease.
    Wang N; Gray M; Lu XH; Cantle JP; Holley SM; Greiner E; Gu X; Shirasaki D; Cepeda C; Li Y; Dong H; Levine MS; Yang XW
    Nat Med; 2014 May; 20(5):536-41. PubMed ID: 24784230
    [TBL] [Abstract][Full Text] [Related]  

  • 47. "Brain training" improves cognitive performance and survival in a transgenic mouse model of Huntington's disease.
    Wood NI; Glynn D; Morton AJ
    Neurobiol Dis; 2011 Jun; 42(3):427-37. PubMed ID: 21324361
    [TBL] [Abstract][Full Text] [Related]  

  • 48. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
    Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
    Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.
    Tang TS; Chen X; Liu J; Bezprozvanny I
    J Neurosci; 2007 Jul; 27(30):7899-910. PubMed ID: 17652581
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector.
    Georgievska B; Jakobsson J; Persson E; Ericson C; Kirik D; Lundberg C
    Hum Gene Ther; 2004 Oct; 15(10):934-44. PubMed ID: 15585109
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
    Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
    Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IGF-1 protects against diabetic features in an in vivo model of Huntington's disease.
    Duarte AI; Petit GH; Ranganathan S; Li JY; Oliveira CR; Brundin P; Björkqvist M; Rego AC
    Exp Neurol; 2011 Oct; 231(2):314-9. PubMed ID: 21763311
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration.
    Díaz-Hernández M; Díez-Zaera M; Sánchez-Nogueiro J; Gómez-Villafuertes R; Canals JM; Alberch J; Miras-Portugal MT; Lucas JJ
    FASEB J; 2009 Jun; 23(6):1893-906. PubMed ID: 19171786
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bone marrow mesenchymal stem cells can improve the motor function of a Huntington's disease rat model.
    Jiang Y; Lv H; Huang S; Tan H; Zhang Y; Li H
    Neurol Res; 2011 Apr; 33(3):331-7. PubMed ID: 21513650
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease.
    Saydoff JA; Garcia RA; Browne SE; Liu L; Sheng J; Brenneman D; Hu Z; Cardin S; Gonzalez A; von Borstel RW; Gregorio J; Burr H; Beal MF
    Neurobiol Dis; 2006 Dec; 24(3):455-65. PubMed ID: 17011205
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration.
    Strand AD; Baquet ZC; Aragaki AK; Holmans P; Yang L; Cleren C; Beal MF; Jones L; Kooperberg C; Olson JM; Jones KR
    J Neurosci; 2007 Oct; 27(43):11758-68. PubMed ID: 17959817
    [TBL] [Abstract][Full Text] [Related]  

  • 57. p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease.
    Park KHJ; Franciosi S; Parrant K; Lu G; Leavitt BR
    Neuroscience; 2017 Jun; 352():79-87. PubMed ID: 28391013
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dose-dependent neuroprotection of VEGF₁₆₅ in Huntington's disease striatum.
    Ellison SM; Trabalza A; Tisato V; Pazarentzos E; Lee S; Papadaki V; Goniotaki D; Morgan S; Mirzaei N; Mazarakis ND
    Mol Ther; 2013 Oct; 21(10):1862-75. PubMed ID: 23799534
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disease Modification Through Trophic Factor Delivery.
    Savolainen M; Emerich D; Kordower JH
    Methods Mol Biol; 2018; 1780():525-547. PubMed ID: 29856034
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.
    Dai Y; Dudek NL; Li Q; Fowler SC; Muma NA
    J Neurosci; 2009 Sep; 29(37):11550-9. PubMed ID: 19759302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.